Page last updated: 2024-10-30

metformin and Infant, Newborn, Diseases

metformin has been researched along with Infant, Newborn, Diseases in 11 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Infant, Newborn, Diseases: Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.

Research Excerpts

ExcerptRelevanceReference
"In this study, we observed a high percentage of SGA births among women with type 2 diabetes and chronic hypertension and/or nephropathy who were treated with metformin."9.51Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? ( Asztalos, E; Donovan, LE; Feig, DS; Murphy, KE; Sanchez, JJ; Shah, PS; Tomlinson, G; Zinman, B, 2022)
"The results of this trial will inform endocrinologists, obstetricians, family doctors, and other healthcare professionals caring for women with type 2 diabetes in pregnancy, as to the benefits of adding metformin to insulin in this high risk population."9.22Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. ( Armson, AB; Asztalos, E; Barrett, JF; Fantus, IG; Feig, DS; Lipscombe, LL; Murphy, K; Ohlsson, A; Ryan, EA; Sanchez, J; Tomlinson, G; Zinman, B, 2016)
"To review pregnancy outcomes in women with Type 2 diabetes (Type 2 DM), comparing women treated with those not treated with metformin."7.73Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006)
"In this study, we observed a high percentage of SGA births among women with type 2 diabetes and chronic hypertension and/or nephropathy who were treated with metformin."5.51Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? ( Asztalos, E; Donovan, LE; Feig, DS; Murphy, KE; Sanchez, JJ; Shah, PS; Tomlinson, G; Zinman, B, 2022)
"This is a randomized double-blind multi-center clinical trial of insulin plus metformin versus insulin plus placebo for the treatment of type 2 diabetes complicating pregnancy."5.27Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study. ( Berry, DC; Boggess, K; de Los Angeles Abreu, M; Dorman, KF; Ivins, AR; Thomas, SD; Young, L, 2018)
"The results of this trial will inform endocrinologists, obstetricians, family doctors, and other healthcare professionals caring for women with type 2 diabetes in pregnancy, as to the benefits of adding metformin to insulin in this high risk population."5.22Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial. ( Armson, AB; Asztalos, E; Barrett, JF; Fantus, IG; Feig, DS; Lipscombe, LL; Murphy, K; Ohlsson, A; Ryan, EA; Sanchez, J; Tomlinson, G; Zinman, B, 2016)
"To review pregnancy outcomes in women with Type 2 diabetes (Type 2 DM), comparing women treated with those not treated with metformin."3.73Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome? ( Hughes, RC; Rowan, JA, 2006)
"The prevalence of pre-eclampsia was significantly increased in the group of women treated with metformin compared to women treated with sulphonylurea or insulin (32 vs."3.70Oral hypoglycaemic agents in 118 diabetic pregnancies. ( Damm, P; Hellmuth, E; Mølsted-Pedersen, L, 2000)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Metformin appears to be an effective treatment for women with GDM and may reduce risk of some adverse neonatal outcomes when compared with insulin."1.51Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. ( Boggess, K; Engel, SM; Howe, AS; Jonsson Funk, M; Landi, SN; Radke, S; Stürmer, T, 2019)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's3 (27.27)2.80

Authors

AuthorsStudies
Yu, DQ1
Xu, GX1
Teng, XY1
Xu, JW1
Tang, LF1
Feng, C2
Rao, JP1
Jin, M1
Wang, LQ1
Feig, DS2
Zinman, B2
Asztalos, E2
Donovan, LE1
Shah, PS1
Sanchez, JJ1
Tomlinson, G2
Murphy, KE1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Kelty, E1
Tran, DD1
Atkinson, A1
Preen, DB1
Havard, A1
Landi, SN1
Radke, S1
Boggess, K2
Engel, SM1
Stürmer, T1
Howe, AS1
Jonsson Funk, M1
Pearson, ER1
Berry, DC1
Thomas, SD1
Dorman, KF1
Ivins, AR1
de Los Angeles Abreu, M1
Young, L1
Bashir, M1
Dabbous, Z1
Baagar, K1
Elkhatib, F1
Ibrahim, A1
Brich, SA1
Abdel-Rahman, ME1
Konje, JC1
Abou-Samra, AB1
Murphy, K1
Sanchez, J1
Ohlsson, A1
Ryan, EA1
Fantus, IG1
Armson, AB1
Lipscombe, LL1
Barrett, JF1
Hughes, RC1
Rowan, JA1
Hellmuth, E1
Damm, P1
Mølsted-Pedersen, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy[NCT02932475]Phase 3831 participants (Actual)Interventional2017-05-25Terminated (stopped due to Recommendation by the DSMB that the study be stopped for futility)
Metformin in Women With Type 2 Diabetes in Pregnancy Trial[NCT01353391]Phase 3500 participants (Actual)Interventional2011-05-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Infant Fat Mass

Neonatal fat mass measured by skin-fold thickness (anthropometrics).The circumference of the upper limb is the circumference of the upper arm, and the circumference of the lower limb equals the mean of the circumferences measured at the midthigh and calf. The volume of the subcutaneous layer of fat covering each cylinder is estimated by multiplying the length times the circumference times the layer of fat estimated by the skinfold measures. The triceps skinfold measure is used as an estimate of the fat thickness of the limbs, and the subscapular skinfold measure approximates the fat thickness of the trunk. Total body fat is estimated by summing the volumes of fat covering each of the cylinders and multiplying by 0.9 (the density of fat). (NCT02932475)
Timeframe: Within 72 hrs of birth

Interventionkg (Mean)
Maternal Metformin0.46
Maternal Placebo0.5

Number of Participants With Composite Adverse Neonatal Outcome

"Participants with one or more of the following:~capillary blood glucose level of < 30 mg/dL or capillary blood glucose requiring medical treatment, or~Birth trauma (umbilical cord artery pH < 7.0 or shoulder dystocia with brachial plexus injury), or~Hyperbilirubinemia requiring phototherapy, or~Deliver < 37 weeks' gestation, or~Miscarry, are stillborn, experience a neonatal demise, or~Large for gestational age infant (birth weight > 90th percentile for gestational age), or~Small for gestational age infant (birth weight < 10th percentile for gestational age) or low birth weight (< 2500 gm)" (NCT02932475)
Timeframe: An average of 48 hours for term infants and 30 days for preterm infants

InterventionParticipants (Count of Participants)
Metformin269
Placebo277

Maternal Safety Based on Treatment Emergent Adverse Events

Adverse maternal outcomes. (NCT02932475)
Timeframe: An average of 48 hours following delivery

,
InterventionParticipants (Count of Participants)
Any adverse event leading to early study agent discontinuationAny adverse event associated with maternal deathAny adverse event associated with fetal deathAny maternal serious adverse eventAny maternal non-serious adverse event
Metformin13210113149
Placebo20110111157

Neonatal Safety Based on Treatment Emergent Adverse Events

Adverse neonatal outcomes (NCT02932475)
Timeframe: up to 28 days of life

,
InterventionParticipants (Count of Participants)
Any neonatal serious adverse eventAny neonatal non-serious adverse event
Maternal Metformin81157
Maternal Placebo105162

Number of Participants With Maternal Side Effects

"Secondary outcome of maternal side effects were defined as:~clinically relevant hypoglycemia defined as capillary blood glucose < 60 or < 80 with symptoms~GI side effects defined as nausea, vomiting, diarrhea" (NCT02932475)
Timeframe: Throughout study until delivery at 40 weeks gestation

,
InterventionParticipants (Count of Participants)
Clinically relevant hypoglycemiaGastrointestinal side effects
Metformin87182
Placebo85171

Reviews

3 reviews available for metformin and Infant, Newborn, Diseases

ArticleYear
Glycemic control and neonatal outcomes in women with gestational diabetes mellitus treated using glyburide, metformin, or insulin: a pairwise and network meta-analysis.
    BMC endocrine disorders, 2021, Oct-12, Volume: 21, Issue:1

    Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glyburide; Glycemic Control; Humans; Hypoglycem

2021
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Pharmacogenetics and target identification in diabetes.
    Current opinion in genetics & development, 2018, Volume: 50

    Topics: Diabetes Mellitus, Type 2; Genotype; Glucose Transporter Type 2; Hepatocyte Nuclear Factor 1-alpha;

2018

Trials

3 trials available for metformin and Infant, Newborn, Diseases

ArticleYear
Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?
    Diabetes care, 2022, 07-07, Volume: 45, Issue:7

    Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational Age; Humans; Hypertension; Hyp

2022
Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study.
    BMC pregnancy and childbirth, 2018, Dec-12, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Birth Injuries; Diabetes Mellitus, Type 2; Disease Management; Double-Blind Metho

2018
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.
    BMC pregnancy and childbirth, 2016, 07-19, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Blood Glucose; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method

2016

Other Studies

5 other studies available for metformin and Infant, Newborn, Diseases

ArticleYear
Maternal and Neonatal Health Outcomes Associated with the Use of Gliclazide and Metformin for the Treatment of Diabetes in Pregnancy: A Record Linkage Study.
    Diabetes technology & therapeutics, 2020, Volume: 22, Issue:2

    Topics: Abnormalities, Drug-Induced; Adult; Diabetes, Gestational; Female; Gliclazide; Hospitalization; Huma

2020
Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand.
    Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:12

    Topics: Adolescent; Adult; Birth Weight; Cesarean Section; Diabetes, Gestational; Female; Humans; Hypoglycem

2019
Type 2 diabetes mellitus in pregnancy: The impact of maternal weight and early glycaemic control on outcomes.
    European journal of obstetrics, gynecology, and reproductive biology, 2019, Volume: 233

    Topics: Adult; Case-Control Studies; Cesarean Section; Diabetes Mellitus, Type 2; Female; Fetal Macrosomia;

2019
Pregnancy in women with Type 2 diabetes: who takes metformin and what is the outcome?
    Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:3

    Topics: Adult; Body Mass Index; Chronic Disease; Delivery, Obstetric; Diabetes Mellitus, Type 2; Female; Fet

2006
Oral hypoglycaemic agents in 118 diabetic pregnancies.
    Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17, Issue:7

    Topics: Abruptio Placentae; Adult; Birth Weight; Cesarean Section; Cohort Studies; Diabetes Mellitus, Type 2

2000